Affimed Reports Positive Data From AFM24-102 Trial In Heavily Pretreated NSCLC Patients

(RTTNews) - Affimed N.V. (AFMD), Tuesday announced the updated clinical results from the ongoing AFM24-102 trial, evaluating the AFM24/atezolizumab combination therapy in heavily pretreated non-small cell lung cancer or NSCLC patients.

Among the heavily pretreated NSCLC EGFR wild-type patients, the combination therapy demonstrated an overall response rate of 21 percent, and a disease control rate of 76 percent. Moreover, tumor shrank in 48 percent of 33 participants.

Meanwhile, in heavily pretreated NSCLC EGFR mutant patients the combination showed an overall response rate of 24 percent, and a disease control rate of 71 percent. Also, tumor shrank in 41 percent of the total participants.

Additionally, the company reported findings from a post-hoc exposure-response analysis in patients treated with 480 mg AFM24 showing higher AFM24 exposure is associated with significantly better response rates, improved progression-free survival, and overall survival.

Based on these findings, the company plans to use a dose of 720 mg of the combination weekly for the future development program of AFM24.

During the pre-market hours, Affimed's stock is moving down 6.10 percent, to $2.00 on the Nasdaq.